Health Care/Hospital News & Press Release Distribution

Health Care/Hospital

APAC
Global

Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology

SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first recorded tria...

2024-02-21 22:00 1289

WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

* Named Top-Rated for fourth consecutive year * Committed to generating long-term value for all stakeholders SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has ...

2024-02-21 18:00 2557

Lanvin Group Resiliency was Key in 2023, Preliminary Revenues Up 1% Year-on-Year

* Revenue of €426 million for FY2023, a 1% increase over FY 2022 * Despite challenging conditions, Lanvin Group grew revenue by 8% in APAC * Resiliency through creative transition at Lanvin brand helped improve sales trend in the second half of 2023 * Positive signals in the DTC channel, in...

2024-02-21 18:00 2760

Zylox-Tonbridge Receives Marketing Approvals for Multiple Products in the UAE

HANGZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK), a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in theUnited Arab Emirates for five of i...

2024-02-21 16:16 1045

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

PORTO, Portugal, Feb. 21, 2024 /PRNewswire/ -- A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine , a300,000 Euro prize promoted by the BIAL Foundation

2024-02-21 16:00 1398

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical Association•Neurology (JAMA NEUROLOGY, IF: 29.0) published online the key findings of a phase III clinical study (NCT04950920) (the "TASTE-SL Study") investigating Sanbexin® (a combination of edara...

2024-02-21 12:26 1855

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. ( Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; "Inveni...

2024-02-21 11:56 1072

Datasea Establishes Joint Venture Company to Further Penetrate the Estimated Approximately 527.8 billion US Dollars 5G Market in China

New Entity to be Focused on Increasing Scale of Datasea's 5G Services Utilizing Artificial Intelligence, which is Expected to Drive Significant Revenue in 2024 BEIJING, Feb. 20, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology ...

2024-02-21 01:31 1251

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors again...

2024-02-20 22:30 1342

Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711

SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Admi...

2024-02-20 22:00 1174

FDA Grants Orphan Drug Designation to 9MW3011

SHANGHAI, Feb. 20, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...

2024-02-20 22:00 1186

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...

2024-02-20 21:00 2765

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

HEFEI, China, Feb. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced th...

2024-02-20 20:00 1049

Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price

BEIJING, Feb. 20, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter (the "Letter") from t...

2024-02-20 20:00 2488

Bowtie Term CI Early Stage and Multiple Cover is rated top in the industry Examining its advantages from the product design perspective

HONG KONG, Feb. 20, 2024 /PRNewswire/ -- In December 2023, Bowtie launched a new Term Critical Illness Insurance product calledBowtie Term CI Early Stage and Multiple Cover . Shortly after it is launched, it was rated top by the independent...

2024-02-20 14:59 1318

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays. The company has successfully secured significant deals with indu...

2024-02-20 14:00 1363

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

Mount Alvernia Hospital Elevates Holistic Healthcare with OutSystems

Using the low-code platform, the hospital's in-house developers saved half the time it typically takes to develop applications for staff, patients and visitors. SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- Mount Alvernia Hospital has partnered with OutSystems, a global leader in high-performance low...

2024-02-20 14:00 1703

Mount Alvernia Hospital Elevates Holistic Healthcare with OutSystems

Ciracle Cosmeceutical Brand to Host " Pore Control Blackhead Off Sheet" Experience Influencer Recruitment Event

SEOUL, South Korea, Feb. 19, 2024 /PRNewswire/ -- Ciracle, a cosmeceutical brand dedicated to pursuing skin health, will be hosting an influencer recruitment eventto experience the "Pore Control Blackhead Off Sheet" and other Ciracle products on its SNS platforms starting aroundthis April.

2024-02-20 13:28 1300

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2024-02-20 08:22 2528

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 1631

1 ... 28 29 303132 33 34 ... 807